<![CDATA[Pembrolizumab Plus EV Regimens Receive FDA Approval for Muscle Invasive Bladder Cancer]]>

<![CDATA[FDA OKs Pembrolizumab/EV Combo in Muscle Invasive Bladder Cancer]]>

FDA Approves Perioperative Pembrolizumab Plus Enfortumab Vedotin for Muscle-Invasive Bladder Cancer

July 10, 2026 The U.S. Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-

FDA Expands Approval of Chemo-Free Bladder Cancer Combo in Curative Setting

(MedPage Today) -- The FDA approved pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa (Keytruda Qlex) in combination with

<![CDATA[FDA Clears IND For UGN-501 in Non-Muscle Invasive Bladder Cancer]]>

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in p

Tom Powles: The FDA Approval of Perioperative EVP in Bladder Cancer is a Landmark Moment

Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X: “The FDA approval of perioperative EVP in muscle inv